Chugai and Takeda Collaborate to Evaluate the Combination Therapy for Multiple Tumor Types in Japan
Shots:
- Following a joint clinical research agreement between Roche and Exelixis and in conjunction with certain rights granted in Japan- Chugai and Takeda will study Tecentriq (atezolizumab) and Cabometyx (cabozantinib) as a combination therapy in Japan
- The three global P- III CONTACT studies are ongoing to investigate the combination of atezolizumab and cabozantinib as a potential new treatment option in multiple tumor types- and Chugai and Takeda are planning to join in supporting P-III studies in Japan
- Tecentriq is a mAb targeting PD-L1- acts by blocking is its interactions with both PD-1 and B7.1 receptor. Cabometyx is approved for advanced RCC and for HCC prior treated with sorafenib in the US
Click here to read full press release/ article
Ref: Chugai | Image: Takeda
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com